Neonatal acyclovir pharmacokinetics in patients with herpes virus infections.
A preliminary analysis is presented of the pharmacokinetics of acyclovir in neonatal patients with herpes simplex virus infections. Mean peak acyclovir levels (microM +/- SD) at 5, 10, and 15 mg/kg per dose were 30.0 +/- 9.9, 61.2 +/- 18.3, and 86.1 +/- 23.5, with corresponding mean trough levels (microM +/- SD) of 5.3 +/- 3.4, 10.1 +/- 8.4, and 13.8 +/- 11.1, respectively. The mean half-life (t 1/2 beta) of acyclovir was 3.78 +/- 1.21 hours. The mean percent urinary recovery of acyclovir (+/- SD) at each dosage level was similar, with an overall mean recovery of 65 percent. The mean acyclovir concentration in urine did not exceed the solubility of acyclovir in bladder urine (1,300 micrograms/ml). Generally, neonatal acyclovir pharmacokinetics was consistent with previous reports from studies of adults.
D000212:Acyclovir; D000998:Antiviral Agents / Q000008:administration & dosage / Q000378:metabolism*; D003586:Cytomegalovirus Infections / Q000378:metabolism; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D006561:Herpes Simplex / Q000378:metabolism; D006566:Herpesviridae Infections / Q000378:metabolism*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000378:metabolism*; D007263:Infusions, Parenteral; D007700:Kinetics
D000998:Antiviral Agents; D006147:Guanine; D000212:Acyclovir